PDF (4205K)
摘要
结直肠癌(colorectal cancer,CRC)是世界上最常见的癌症之一,近年来其发病率呈不断上升的趋势。对 CRC 开展的临床研究和在动物模型得到的实验证据将肠道菌群与 CRC 联系起来,肠道菌群作为 CRC 发生发展的关键调节因子,主要通过塑造局部免疫与炎症微环境、产生具有抑癌或促癌活性的代谢物,以及分泌基因毒性物质等多种机制,驱动 CRC 的发生发展。与此同时,肠道菌群也可通过多重机制影响 CRC 对化疗和免疫治疗的敏感性。本文旨在探讨与 CRC 发生发展以及治疗密切相关的特定菌群,重点介绍肠道菌群介导的 CRC 的发病机制以及目前有效的治疗手段,以期推动对肠道菌群与 CRC 更深层次关系的研究,并为提升 CRC 的疗效提供新的研究策略。
Abstract
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, and its incidence has shown a steadily increasing trend in recent years. Clinical investigations and experimental evidence from animal models have established a strong association between the gut microbiota and CRC. The gut microbiota functions as a key regulatory factor in the initiation and progression of CRC, primarily through shaping the local immune and inflammatory microenvironment, producing metabolites with either tumor-suppressive or tumor-promoting activities, and secreting genotoxic substances, among other mechanisms, thereby driving CRC development. Meanwhile, the gut microbiota can also modulate the sensitivity of CRC to chemotherapy and immunotherapy through multiple pathways. This review aims to explore specific microbial taxa closely related to CRC onset, progression, and treatment, with a particular focus on the gut microbiota–mediated pathogenic mechanisms of CRC and currently effective therapeutic strategies. Ultimately, this work seeks to advance understanding of the deeper interplay between the gut microbiota and CRC, while providing novel perspectives for improving therapeutic efficacy in CRC.
关键词
Key words
[Author(id=1330571698903347505, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=3309791181@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571698966262068, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, authorId=1330571698903347505, language=EN, stringName=Wei LIU, firstName=Wei, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571699016593718, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, authorId=1330571698903347505, language=CN, stringName=刘威, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中南大学湘雅医院 临床药理研究所,长沙 410008,湖南, bio={"content":"刘威,男,研究方向:药物基因组学。 E-mail:3309791181@qq.com
"}, bioImg=null, bioContent=刘威,男,研究方向:药物基因组学。 E-mail:3309791181@qq.com
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571698827850027, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, xref=null, ext=[AuthorCompanyExt(id=1330571698844627245, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, companyId=1330571698827850027, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China), AuthorCompanyExt(id=1330571698857210158, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, companyId=1330571698827850027, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中南大学湘雅医院 临床药理研究所,长沙 410008,湖南)])]), Author(id=1330571699062731064, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=yjsd2003@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330571699134034235, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, authorId=1330571699062731064, language=EN, stringName=Wei ZHANG, firstName=Wei, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571699184365885, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, authorId=1330571699062731064, language=CN, stringName=张伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中南大学湘雅医院 临床药理研究所,长沙 410008,湖南, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571698827850027, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, xref=null, ext=[AuthorCompanyExt(id=1330571698844627245, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, companyId=1330571698827850027, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China), AuthorCompanyExt(id=1330571698857210158, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330547045706838634, companyId=1330571698827850027, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中南大学湘雅医院 临床药理研究所,长沙 410008,湖南)])])]
刘威,张伟.
肠道菌群与结直肠癌:从发病机制到治疗干预的研究进展[J].
中国临床药理学与治疗学, 2026, 31(7): 937-947 DOI:10.12092/j.issn.1009-2501.2026.07.010
| [1] |
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J].Lancet, 2019, 394(10207): 1467-1480.
|
| [2] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2024, 74(3): 229-263.
|
| [3] |
Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy[J].Nat Rev Clin Oncol, 2023, 20(7): 429-452.
|
| [4] |
Si H, Yang Q, Hu H, et al. Colorectal cancer occurrence and treatment based on changes in intestinal flora[J].Semin Cancer Biol, 2021, 70: 3-10.
|
| [5] |
Guinane CM, Cotter PD.Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ[J].Therap Adv Gastroenterol, 2013, 6(4): 295-308.
|
| [6] |
Tong G, Shen Y, Li H, et al. NLRC4, inflammation and colorectal cancer (Review)[J].Int J Oncol, 2024, 65(4): 99.
|
| [7] |
Wang N, Fang JY.Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer[J].Trends Microbiol, 2023, 31(2): 159-172.
|
| [8] |
Guo P, Tian Z, Kong X, et al. FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2[J].J Exp Clin Cancer Res, 2020, 39(1): 202.
|
| [9] |
Zhang L, Leng XX, Qi J, et al. The adhesin RadD enhances Fusobacterium nucleatum tumour colonization and colorectal carcinogenesis[J].Nat Microbiol, 2024, 9(9): 2292-2307.
|
| [10] |
Casasanta MA, Yoo CC, Udayasuryan B, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration[J].Sci Signal, 2020, 13(641): eaba9157.
|
| [11] |
Peng C, Ouyang Y, Lu N, et al. The NF-κB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: recent advances[J].Front Immunol, 2020, 11: 1387.
|
| [12] |
Hibino S, Kawazoe T, Kasahara H, et al. Inflammation-induced tumorigenesis and metastasis[J].Int J Mol Sci, 2021, 22(11): 5421.
|
| [13] |
Chung L, Orberg ET, Geis AL, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells[J].Cell Host Microbe, 2018, 23(3): 421.
|
| [14] |
Huang P, Ji F, Ho-Kwan Cheung A, et al. Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK[J].Cell Host Microbe, 2025, 33(5): 759-760.
|
| [15] |
Zhao L, Zhang X, Zhou Y, et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients[J].Oncogene, 2022, 41(36): 4200-4210.
|
| [16] |
Wang X, Huycke MM.Colorectal cancer: role of commensal bacteria and bystander effects[J].Gut Microbes, 2015, 6(6): 370-376.
|
| [17] |
Wang Y, Zhang Y, Wang Z, et al. A clinical nomogram incorporating salivary Desulfovibrio desulfuricans level and oral hygiene index for predicting colorectal cancer[J].Ann Transl Med, 2021, 9(9): 754.
|
| [18] |
He Z, Wu J, Gong J, et al. Microbiota in mesenteric adipose tissue from Crohn's disease promote colitis in mice[J].Microbiome, 2021, 9(1): 228.
|
| [19] |
Tomkovich S, Yang Y, Winglee K, et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis[J].Cancer Res, 2017, 77(10): 2620-2632.
|
| [20] |
Zhang X, Yu D, Wu D, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance[J].Cell Host Microbe, 2023, 31(3): 418-432. e418.
|
| [21] |
Ternes D, Tsenkova M, Pozdeev VI, et al. Author correction: the gut microbial metabolite formate exacerbates colorectal cancer progression[J].Nat Metab, 2023, 5(9): 1638.
|
| [22] |
Okumura S, Konishi Y, Narukawa M, et al. Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion[J].Nat Commun, 2021, 12(1): 5674.
|
| [23] |
He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity[J].Cell Metab, 2021, 33(5): 988-1000. e1007.
|
| [24] |
Bultman SJ, Jobin C. Microbial-derived butyrate: an oncometabolite or tumor-suppressive metabolite ?[J].Cell Host Microbe, 2014, 16(2): 143-145.
|
| [25] |
Ocvirk S, O'keefe SJD. Dietary fat, bile acid metabolism and colorectal cancer[J].Semin Cancer Biol, 2021, 73: 347-355.
|
| [26] |
Cong J, Liu P, Han Z, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions[J].Immunity, 2024, 57(4): 876-889. e811.
|
| [27] |
Rivas-Domínguez A, Pastor N, Martínez-López L, et al. The role of DNA damage response in dysbiosis-induced colorectal cancer[J].Cells, 2021, 10(8): 1934.
|
| [28] |
Zhang W, Qin X, Zhang K, et al. Correction to: microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling[J].Cell Oncol (Dordr), 2024, 47(4): 1201-1204.
|
| [29] |
Ren YM, Zhuang ZY, Xie YH, et al. BCAA-producing clostridium symbiosum promotes colorectal tumorigenesis through the modulation of host cholesterol metabolism[J].Cell Host Microbe, 2024, 32(9): 1519-1535. e1517.
|
| [30] |
Cui W, Guo M, Liu D, et al. Gut microbial metabolite facilitates colorectal cancer development via ferroptosis inhibition[J].Nat Cell Biol, 2024, 26(1): 124-137.
|
| [31] |
Zhang Q, Zhao Q, Li T, et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8(+) T cell immunity[J].Cell Metab, 2023, 35(6): 943-960. e949.
|
| [32] |
Su ACY, Ding X, Lau HCH, et al. Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase[J].Gut, 2024, 73(9): 1478-1488.
|
| [33] |
Yu J, Feng L, Luo Z, et al. Interleukin-10 deficiency suppresses colorectal cancer metastasis by enriching gut Parabacteroides distasonis[J].J Adv Res, 2024, 58: 229-242.
|
| [34] |
Hu M, Xu Y, Wang Y, et al. Gut microbial-derived N-acetylmuramic acid alleviates colorectal cancer via the AKT1 pathway[J].Gut, 2025, 74(8): 1230-1245.
|
| [35] |
Chen Y, Fang H, Chen H, et al. Bifidobacterium inhibits the progression of colorectal tumorigenesis in mice through fatty acid isomerization and gut microbiota modulation[J].Gut Microbes, 2025, 17(1): 2464945.
|
| [36] |
Qu R, Zhang Y, Kim B, et al. Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18: 1/26: 0) and delay colorectal cancer progression[J].Cell Metab, 2025, 33(7): 1187-1202. e5.
|
| [37] |
Li Q, Chan H, Liu W X, et al. Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice[J].Cancer Cell, 2023, 41(8): 1450-1465. e1458.
|
| [38] |
Wolf PG, Cowley ES, Breister A, et al. Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer[J].Microbiome, 2022, 10(1): 64.
|
| [39] |
Clay SL, Fonseca-Pereira D, Garrett WS.Colorectal cancer: the facts in the case of the microbiota[J].J Clin Invest, 2022, 132(4): 5867.
|
| [40] |
Cao Y, Oh J, Xue M, et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites[J].Science, 2022, 378(6618): eabm3233.
|
| [41] |
Mirzarazi M, Bashiri S, Hashemi A, et al. The OmpA of commensal Escherichia coli of CRC patients affects apoptosis of the HCT116 colon cancer cell line[J].BMC Microbiol, 2022, 22(1): 139.
|
| [42] |
Mezerová K, Starý L, Zbořil P, et al. Cyclomodulins and hemolysis in E. coli as potential low-cost non-invasive biomarkers for colorectal cancer screening[J].Life (Basel), 2021, 11(11): 1165.
|
| [43] |
Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21[J].Gastroenterol, 2017, 152(4): 851-866. e824.
|
| [44] |
Chen S, Zhang L, Li M, et al. Fusobacterium nucleatum reduces METTL3-mediated m(6)A modification and contributes to colorectal cancer metastasis[J].Nat Commun, 2022, 13(1): 1248.
|
| [45] |
Sougiannis AT, Vanderveen BN, Enos RT, et al. Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota[J].Brain Behav Immun, 2019, 80: 44-55.
|
| [46] |
Yuan X, Xue J, Tan Y, et al. Albuca bracteate polysaccharides synergistically enhance the anti-tumor efficacy of 5-fluorouracil against colorectal cancer by modulating β-Catenin signaling and intestinal flora[J].Front Pharmacol, 2021, 12: 736627.
|
| [47] |
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J].Cell, 2017, 170(3): 548-563. e516.
|
| [48] |
Ding X, Ting NL, Wong CC, et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity[J].Cell Host Microbe, 2025, 33(6): 941-956. e910.
|
| [49] |
Kalasabail S, Engelman J, Zhang LY, et al. A perspective on the role of microbiome for colorectal cancer treatment[J].Cancers (Basel), 2021, 13(18): 4623.
|
| [50] |
Nakao T, Kurita N, Komatsu M, et al. Irinotecan injures tight junction and causes bacterial translocation in rat[J].J Surg Res, 2012, 173(2): 341-347.
|
| [51] |
Palko-Łabuz A, Maksymowicz J, Sobieszczańska B, et al. Newly obtained apple pectin as an adjunct to irinotecan therapy of colorectal cancer reducing E. coli adherence and β-glucuronidase activity[J].Cancers (Basel), 2021, 13(12): 3014.
|
| [52] |
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J].Science, 2015, 350(6264): 1079-1084.
|
| [53] |
Jia D, Wang Q, Qi Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer[J].Cell, 2024, 187(7): 1651-1665. e1621.
|
| [54] |
Kang X, Liu C, Ding Y, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells[J].Gut, 2023, 72(11): 2112-2122.
|
| [55] |
Wang X, Fang Y, Liang W, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer[J].Cancer Cell, 2025, 43(3): 564-574.
|
| [56] |
Gao Y, Bi D, Xie R, et al. Correction to: fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer[J].Signal Transduct Target Ther, 2021, 6(1): 434.
|
| [57] |
Jiang SS, Xie YL, Xiao XY, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer[J].Cell Host Microbe, 2023, 31(5): 781-797. e789.
|
| [58] |
Liu Y, Wong CC, Ding Y, et al. Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice[J].Nat Microbiol, 2024, 9(6): 1467-1482.
|
| [59] |
Andrews MC, Duong CP, Gopalakrishnan V, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade[J].Nat Med, 2021, 27(8): 1432-1441.
|
| [60] |
Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J].Ann Oncol, 2018, 29(6): 1437-1444.
|
| [61] |
Bakuradze N, Merabishvili M, Makalatia K, et al. In vitro evaluation of the therapeutic potential of phage VA7 against enterotoxigenic bacteroides fragilis infection[J].Viruses, 2021, 13(10): 2044.
|
| [62] |
Lin Y, Xie M, Lau HC, et al. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response[J].Med, 2025, 6(3): 100530.
|
| [63] |
Sugimura N, Li Q, Chu ESH, et al. Lactobacillus gallinarum modulates the gut microbiota and produces an anti-cancer metabolites to protect against colorectal tumourigenesis[J].Gut, 2021, 71(10): 2011-2021.
|
| [64] |
Fong W, Li Q, Ji F, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis[J].Gut, 2023, 72(12): 2272-2285.
|
| [65] |
Sun Y, Wang Q, Jiang Y, et al. Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis[J].Gut Microbes, 2025, 17(1): 2449111.
|
| [66] |
Si W, Liang H, Bugno J, et al. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade[J].Gut, 2022, 71(3): 521-533.
|
| [67] |
Zhao W, Lei J, Ke S, et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)[J].EClinicalMedicine, 2023, 66: 102315.
|
| [68] |
Davar D, Dzutsev AK, Mcculloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J].Science, 2021, 371(6529): 595-602.
|
| [69] |
Nan K, Zhong Z, Yue Y, et al. Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8(+) T cells[J].Gut, 2025, 74(5): 775-786.
|
基金资助
国家自然科学基金(82373961)